Needham & Company
-
Heron Therapeutics to Present at the 21st Annual Virtual Needham Healthcare Conference
-
Heron Therapeutics (HRTX) PT Lowered to $16 at Needham & Company on Financial Overhang Concerns
-
Heron Therapeutics (HRTX) PT Lowered to $24 at Needham & Company, Following Earnings
-
Heron Therapeutics (HRTX) PT Lowered to $28 at Needham & Company
-
Heron Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference
-
Heron Therapeutics (HRTX) Pricing 8.57M Share Offering at $17.50/Sh
-
Heron Therapeutics Announces Pricing of Public Offering of Common Stock
-
Heron Therapeutics (HRTX) Announces Proposed Common Offering
-
Heron Therapeutics Announces Proposed Public Offering of Common Stock
-
Heron Therapeutics (HRTX) PT Lowered to $52 at Needham & Company
-
Heron Therapeutics (HRTX): FDA Priority Review for HTX-011 Seen as 'Significant Positive' - Needham & Company
-
Heron Therapeutics (HRTX) PT Raised to $66 at Needham & Company
-
Heron Therapeutics to Present at the 17th Annual Needham Healthcare Conference
-
Heron Therapeutics (HRTX) PT Raised to $42 at Needham & Company
-
Heron Therapeutics (HRTX) PT Raised to $30 at Needham & Company
-
Heron Therapeutics to Present at the 16th Annual Needham Healthcare Conference
-
Needham & Company Starts Heron Therapeutics (HRTX) at Buy, $28 PT
-
Notable 52-Week Highs and Lows 6/3: (WEN) (HRTX) (ETFC) High; (BTU) (VRA) (VMEM) Low

